Chronic Pancreatitis and Exocrine Pancreatic Insufficiency

Build the diagnosis from structure and function

No single test captures every stage of chronic pancreatitis or proves exocrine failure.

Use pancreas-protocol CT or MRI as first-line cross-sectional imaging for suspected chronic pancreatitis; calcifications, atrophy, duct dilation, strictures, stones, and pseudocysts support established disease.

MRI with MRCP better maps ducts and fluid, and secretin-enhanced MRCP can increase sensitivity when suspicion remains high; EUS can detect subtle parenchymal and ductal features but should not convert nonspecific minor changes into a diagnosis.

Fecal elastase is the most practical initial test for exocrine pancreatic insufficiency and must be measured on a semi-solid or solid stool sample; imaging diagnoses pancreatic disease but cannot itself diagnose exocrine insufficiency.

Chronic pancreatitis is a final pathway, not one exposure

Different insults converge on fibrosis, acinar loss, duct distortion, and progressive functional failure.

Alcohol is an important toxic cause, but tobacco independently increases risk and progression; neither exposure should be treated as the only possible explanation.

Genetic susceptibility involving PRSS1, SPINK1, CFTR, CTRC, or other pathways is especially important in young patients, recurrent idiopathic attacks, and families with pancreatitis.

Recurrent severe acute pancreatitis, pancreatic duct obstruction, pancreas divisum in selected patients, hypercalcemia or hypertriglyceridemia, and autoimmune pancreatitis can also produce chronic injury.

Alcohol is a cause, not a permission slip to stop the workup.

Dose and thresholds make replacement testable

Turn vague enzyme advice into an observable nutrition plan.

Fecal elastase below 100 micrograms per gram strongly supports exocrine insufficiency, while 100 to 200 is indeterminate and should trigger contextual reassessment.

An adult starting dose is at least 40,000 USP lipase units with each meal and about 20,000 with snacks, taken during eating and increased when symptoms or nutritional markers remain abnormal.

Record baseline body mass index, muscle status, fat-soluble vitamin levels, and bone density; repeat dual-energy x-ray absorptiometry every 1 to 2 years in patients with exocrine insufficiency.

PERT has a dose, a clock, and measurable endpoints.

Fibrosis disrupts both the duct and the gland

Pain, maldigestion, and diabetes arise from different compartments of the same scarred organ.

Intraductal protein plugs, stones, and strictures can raise upstream pressure and contribute to pain, while parenchymal fibrosis and acinar loss reduce digestive enzyme and bicarbonate delivery.

Advanced islet injury produces pancreatogenic diabetes, often called type 3c diabetes, with loss of insulin and sometimes impaired glucagon counterregulation.

Anatomy also predicts complications: pseudocysts can compress stomach or bile duct, splenic vein thrombosis can create isolated gastric varices, and pseudoaneurysm can cause life-threatening hemorrhage.

Fecal elastase is useful only in context

A low number can support exocrine insufficiency, but specimen quality and pretest probability decide how much to trust it.

A fecal elastase value below 100 micrograms per gram on a semi-solid or solid specimen provides good evidence of exocrine pancreatic insufficiency; 100 to 200 is indeterminate.

Watery diarrhea can dilute the sample and create a falsely low value, while a normal result is less reassuring when pretest probability is very high.

Response to an empiric pancreatic enzyme trial is unreliable as a diagnostic test because symptoms and adherence vary; make the diagnosis first, then use response to monitor treatment.

Formed stool first; number second.

Treat the cause, replace the missing function, and decompress selectively

A useful plan addresses exposure, nutrition, pain mechanism, duct anatomy, and endocrine failure together.

Support complete alcohol abstinence and tobacco cessation, treat metabolic drivers, and use genetic counseling or autoimmune therapy when the causal phenotype warrants it.

Once exocrine pancreatic insufficiency is diagnosed, prescribe pancreatic enzyme replacement therapy during meals: start adults with at least 40,000 USP lipase units per meal and about half with snacks, then titrate to meal size, fat content, symptoms, weight, and vitamin recovery.

Use frequent smaller meals and a low-moderate fat diet rather than a very-low-fat diet; involve a dietitian, monitor fat-soluble vitamins and bone health, and add acid suppression when needed for non-enteric-coated enzymes or inadequate response after adherence and dose are checked.

Use stepwise nonopioid and selected adjunctive analgesia while treating obstruction and complications. Pancreatic enzymes should not be prescribed solely as a reliable pain treatment.

For painful chronic pancreatitis with an obstructed main duct, obtain multidisciplinary surgical input before prolonged endoscopic therapy when the patient is a surgical candidate; endoscopy remains important for selected stones, strictures, pseudocysts, and patients favoring or requiring a less invasive approach.